HopeStage
Back to all studies
UnknownNCT06530290

Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients

Medication studyAges 18+Iran
The study in practice

Understand this study

Who could participate?

Listed age limits: from 18 years.

Listed locations
TehranSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: June 1, 2022
Recruitment status
Unknown
Enrollment listed in the registry
64
Sponsor
Leila Dargahi. PharmD PhD
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Iran
Age range
Over 18 Years
Official registry ID
NCT06530290
Official title
Show the full official title

Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients; a Randomized Double-blinded Placebo-controlled Clinical Trial

Recruitment & locations

Status unknown

Tehran

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Leila Dargahi. PharmD PhD.

Does this study involve medication?

Yes. The study involves medication, including Mirtazapine 15 MG and Placebo.

Who can participate?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies